Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05903027Recruiting

Gepant treAtments: EffectIveNess and tolERability (GAINER)

Role: collaborator

NCT06409832Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Role: collaborator

NCT05903040Completed

Ditan Acute tReatments: Effectiveness and Tolerability (DART)

Role: collaborator

All 3 trials loaded